Cleveland Clinic's Department of Nuclear Medicine facility allows for optimal state-of-the-art imaging for the oncology patients. Our most common requests are for staging and restaging after therapy of lymphoma, melanoma and esophageal, head & neck, lung, colon and breast cancer. With new Medicare (NOPR II) guidelines, patients are covered for PET/CT scans for virtually any solid tumor including brain, pancreatic, thyroid, GIST, sarcomas, gynecologic, prostate, and testicular. Molecular and functional imaging techniques and targeted isotope therapies are some of the most powerful tools available for diagnosis and treatment of your oncology patient. Our physicians are always ready to provide personal consultations on a case by case basis. These are our strengths:

  • Three State of the Art PET/CT cameras
    • Biograph 16 (slice).
    • Biograph 40 (slice) which features “high definition” resolution recovery techniques for more detailed images.
    • 128 slice mCT (molecular PET/CT) which has an extra large bore and time-of-flight acquisition capabilities for the highest resolution PET/CT images available to date.
  • Flat palates and positioning lasers to perform PET/CT simulation using 18-FDG-PET for treatment planning of Radiation Oncology patients.
  • Multidisciplinary Center for PET and Molecular Imaging
    • 5 nuclear medicine physicians and 15 radiologists from various sections within the Imaging Institute who provide the referring physician a joint PET/CT report. This program received special mention at the Highlights of the Annual Society of Nuclear Medicine meeting.
    • Combination of PET and diagnostic contrast enhanced CT findings gives the referring physician a cohesive and unified assessment of the functional and anatomic state of disease.
    • Actively pursuing and soliciting prospective and retrospective clinical research projects for new imaging and therapy techniques.
  • Fusion of functional and anatomic imaging using SPECT/CT
    • 3 Symbia SPECT/CT cameras which facilitate pinpoint localization of neuroendocrine tumors with In-111 octreotide, neuroblastoma and pheochromocytomas with I-123 MIBG, thyroid cancer with I-123, and metastatic lymph nodes with Tc-99m sulfur colloid.
  • Therapy
    • Radioactive I-131 ablation for thyroid cancer patients and therapy of Graves Disease.
    • Radiomicrosphere therapy or “radioembolization” of hepatocellular carcinoma, colorectal, breast, carcinoid, or other liver metastases with Y-90 TheraSpheres or SIR-Spheres in cooperation with interventional radiology.
    • Sm-153 Quadramet is available for treatment of painful bony metastases, especially in prostate and breast cancers.
    • Radioimmunotherapy with I-131 Bexxar is available in our department for the treatment of refractory lymphoma.
  • Dedicated Full time PET-CT Referral Coordinator to facilitate requests and assist with payer approval.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy